ActiveMSers Forums  

Go Back   ActiveMSers Forums > Forums > Dave's SCT Journey

Thread Tools Display Modes
Old 12-27-2017, 04:44 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is offline
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,506
Default PML appears in long-term follow-up of more than 10 years after HSCT

This is the first case of PML that I've noticed with HSCT. Still powerful results. - D

J Neurol. 2017 Dec 21. doi: 10.1007/s00415-017-8718-2. [Epub ahead of print]

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

Frau J1, Carai M2, Coghe G2, Fenu G2, Lorefice L2, La Nasa G3, Mamusa E2, Vacca A3, Marrosu MG2, Cocco E2.


Autologous hematopoietic stem cell transplantation (aHSCT) is used in aggressive relapsing and progressive multiple sclerosis (MS). The multicentre studies and case series reported have relatively short follow-up.

To evaluate long-term effect and safety of HSCT in MS.

Patients referred to the MS centre of Cagliari and undergoing HSCT were included. Variations in relapses and EDSS before and after HSCT were evaluated by Wilcoxon test. A descriptive analysis was made for other clinical data.

Nine patients (female 6, males 3; 5 relapsing-remitting, 2 secondary progressive, 1 primary progressive, and 1 progressive relapsing) performed HSCT (1999-2006). The median follow-up was 11 years (11-18). Eight patients underwent aHSCT, seven using a low intensity conditioning regimen, and one an intermediate intensity. The primary progressive underwent allogeneic HSCT, due to onco hematological disease. The relapses number decreased in the 2 years following the procedure compared to the two preceding years (p = 0.041). New relapses or disease progressions were observed after a range of 7 (low intensity regimen)-118 (intermediate intensity) months. At last follow-up, the EDSS was stable in two patients, improved in two, and worse in five (maximum 2 EDSS in one patient). Six patients showed new lesions, and seven gadolinium-enhancing on brain MRI after a mean of 23.3 and 19.8 months, respectively. Two serious adverse events were reported: melanoma, and progressive multifocal leukoencephalopathy.

Our results confirm in a long follow-up the efficacy of HSCT in reducing relapses and disability progression. The risk/benefit profile is better for intermediate intensity regimens.
Dave Bexfield
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 09:30 AM.

Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.